Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, forecasts that while both Pfizer's Lipitor and AstraZeneca's Crestor will dominate the dyslipidemia drug market, Lipitor may be the overall winner. In 2002, sales of drugs to treat dyslipdemia exceeded $17 billion in the seven major pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan). According to a new Pharmacor study entitled Dyslipidemia, Lipitor will remain dominant for the next 10 years supported by excellent safety and efficacy data from the Anglo Scandinavian Cardio Outcomes Trial (ASCOT). The study also finds that Schering-Plough/Merck's Zetia will make a splash in the market as both a monotherapy and in combination with simvastatin.
"Zetia will find a niche in combination with statins to treat severely dyslipdidemic patients and in patients refractory to high-dose statin monotherapy," said Mark Thornton, Ph.D, analyst at Decision Resources. "Schering-Plough/Merck can expect Zetia to bring in sales of almost $2 billion as a monotherapy and approaching $5 billion as a fixed-dose combination with simvastatin by 2012."
Dyslipidemia describes any abnormality in serum lipid concentration, be it above or below desired levels. Serum concentrations of low-density lipoprotein (LDL), and triglycerides (TGs) may be raised, or high-density lipoprotein (HDL) may be decreased. The link between elevated serum cholesterol levels and the increased risk for coronary artery disease (CAD) is now supported by overwhelming evidence. Large interventional population studies, such as the West of Scotland Coronary Prevention Study (WOSCOPS), the Scandinavian Simvastatin Survival Study (4S), and more recently the Heart Protection Study (HPS) and Anglo Scandinavia Cardio Outcomes Trial (ASCOT), have demonstrated that lowering cholesterol levels can reduce the incidence of both cardiovascular disease and subsequent mortality.
About Pharmacor from Decision Resources
Pharmacor is a unique family of studies based on primary and secondary research conducted by Decision Resources' on-staff experts. Each comprehensive study assesses a host of market-impacting factors and analyzes the commercial outlook for drugs in research and development. Cardium, Cognos, Immune and Inflammatory Disorders, Infectious Disease, Metabolic Disorders, Psychiatric Disorders, and Onkos concentrate on specific therapeutic areas. Mosaic covers high-interest disease states. Dyslipidemia is a Metabolic study.
About Decision Resources
Decision Resources, Inc. is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at www.decisionresources.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 firstname.lastname@example.org
SOURCE: Decision Resources, Inc.
CONTACT: Elizabeth Marshall for Decision Resources, Inc., +1-781-296-
Web site: http://www.decisionresources.com/